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outcomes. For the purpose of this discussion, we d
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[written] protocol for management of a health care p
important to consider the issues associa ed with mak
diagnosis overall, and specifically in older people in
issues of ageing play a part, and whether these can S38 MJA • Volume 183 NuABSTRACT
What we need to know
• How effective would an algorithm be in helping general 
practitioners diagnose asthma?
• What proportion of older people with undiagnosed asthma 
fail to recognise symptoms?
• What proportion of the population believe asthma does not 
occur in the older population?
• What systems or supports do GPs need to diagnose asthma 
more effectively?
What we need to do
• Work on developing a gold standard for asthma diagnosis.
• Develop prototype algorithms for general practice 
discussion.
• Conduct a general practice study to assess the effectiveness 
of an algorithm.
• In conjunction with GPs, develop a pilot program to increase 
awareness of the current asthma problem.
• Conduct focus-group research to identify why some people 
do not believe they can develop asthma for the first time in 
adult life.
• Conduct focus-group research to identify why some adults do 
not attribute asthma symptoms to asthma.
• Conduct focus groups with GPs to identify what support is 
needed to diagnose asthma more effectively.
• Consult with all stakeholders before an intervention is used.
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• Evaluate any interventions used.rec
no
preA ent study has estimated that the prevalence of undiag-sed asthma in the adult population is 2.3%,1 and that thisvalence almost doubles in those aged over 65 years.2
Given that patients whose asthma is undertreated have worse
outcomes, recognition of people with undiagnosed and untreated
asthma is important.3 Although there is no Level I evidence4 to








dated in an algorithm.
It is difficult to define asthma accurately. The definition of asthma
by the Global Initiative for Asthma6 includes inherent ambiguities
(eg, “episodes are usually associated with widespread but variable
airflow obstruction that is often reversible . . .”). Another issue is the
lack of a gold standard for diagnosing asthma, which has implica-
tions for the sensitivity and specificity of the algorithm. However,
this will be refined in future algorithms, and does not prevent us
from using agreed best practice now.
International guidelines for the diagnosis and management of
asthma suggest that a significant change in forced expiratory volume
in 1 second (FEV1) after use of a bronchodilator is indicative of
asthma. However, the degree of reversibility of airflow restriction
that is considered significant varies between guidelines, from 12% to
15% of the baseline value.6,7 In addition, there is inconsistency
between guidelines as to whether the post-bronchodilator response
should be a percentage of baseline or of predicted FEV1. There is
also controversy surrounding the diagnostic value of the response to
bronchodilator.8 The UK National Institute for Clinical Excellence,
in its recent guideline on chronic obstructive pulmonary disease
(COPD), recommended a 400 mL increase in FEV1 in response to
bronchodilator as diagnostic of asthma.9 Given the relative diagnos-
tic uncertainty, the utility of an algorithm may be in providing a
pathway for an approach to decision-making.
Several complex and possible contributory factors need to be
considered in understanding why asthma is underdiagnosed in
older people, and an algorithm may not be able to address this
problem. Altered perceptions of dyspnoea have been described in
older people,10 and patients under-report symptoms to their
doctor.11 However, the proportions who dismiss their asthma
symptoms as part of the normal ageing process, or deny that they
have symptoms, or experience classical as opposed to non-classical
symptoms of asthma, is unknown. These are barriers to presenta-
tion and not to diagnosis, and should be dealt with in health
education campaigns.
Probably the most relevant issue to consider is the acceptability
and utility to general practitioners of yet another diagnostic
algorithm. After consultation with GPs to determine what would
be useful, feasible and applicable in general practice, given their
brief interactions with patients of all types, it was evident that GPs
would use an algorithm as a reference tool rather than a day-to-day
tool.2 If an algorithm establishes improved decision-making in
general practice for asthma diagnosis, it has served its purpose and
does not need to be used on a daily basis.
GPs also related that they think in terms of “bundles” of
information rather than in a linear (algorithmic) way. An algorithm
developed from these consultations that attempted to accommo-
date this point made by GPs is shown in the Box.
Of equal importance, GPs were unaware of the reported level of
underdiagnosis of asthma and felt strongly that being aware of thismber 1 • 4 July 2005
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consistent with the National Asthma Campaign’s “Could it be
asthma?”, an awareness program promoted to the community and
health professionals. The program was associated with an increase
in self-reported doctor-diagnosed asthma in adults from 5.6% in
1987 to 8.0% in 1990.12 Information technology advances may
make algorithms or pathways more relevant and acceptable to GPs
in the future. Clinical technology advances, supported by evidence
that they work in the relevant clinical setting, will need regular
review and appropriate incorporation into practice.
Is it critical that an algorithm should be able to separate asthma
from COPD? While treatment may seem to be similar for both
diseases, at milder levels of disease there are differences in
treatments and acute outcomes, and at all levels there are differ-
An algorithm to aid in diagnosing asthma in older people
Symptom check
Diagnostic questions to consider
♦ Do you think that your breathing is the same as it was when you were younger?
♦ In the past 12 months have you had:
   • An attack of breathing problems? 
   • Wheezing or whistling in your chest when you did not have a cold? 
♦ In the last 12 months have you woken at night with:
   • Feeling of chest tightness?
   • Shortness of breath? 
   • An attack of coughing?
♦ Have you ever used any puffer medications (yours or anyone else’s)?
♦ Are you a smoker or ex-smoker?
♦ Did you have any allergies as a child?
♦ What type of work have you done for most of your life?
♦ What are your hobbies?
 Asthma COPD
Age at onset Any age Older
Allergy Often Sometimes




Smoking history Sometimes Almost always
Sputum production Seldom Almost always
Main differential diagnoses
Further differential diagnoses to consider
• Respiratory infection • Chronic cough*
• Pulmonary oedema • Congestive cardiac failure
• Interstitial lung disease† • Malignancy
• Asthma as a comorbidity • Aspiration
• Anaemia • Medication‡
COPD = chronic obstructive pulmonary disease. 
* Possible reflux. † Such as fibrosis. ‡ Such as angiotensin-converting enzyme inhibitors, ß-blockers.
COPD = chronic obstructive pulmonary disease. 
FEV1 = forced expiratory volume in 1 second.
FVC = forced vital capacity.
PEF = peak expiratory flow.
Assumptions: spirometry measures are valid and patient adheres 




(Improvement in FEV1 > 12% and 200 mL)
Responsive to trial of therapy




















Spirometry and trial of therapy
Considerations
Relative contraindications for oral steroids
• Diabetes • Tuberculosis
• Hypertension • Peptic ulcers
• Glaucoma • Mood disorders
Spirometry and trial of therapy in older people
can be influenced by social and economic factors






♦ 500–1000 μg fluticasone propionate/day, 800–1600 μg budesonide/day, or equivalent 
 (using a spacer where possible ) for 4–8 weeks.
Oral steroid option
♦ 50 mg oral prednisolone/day for 10–14 days, with or without inhaled steroid.
♦ If benefits are observed, replace prednisolone with inhaled steroid and reassess.
Monitoring and reassessment
♦ Home peak expiratory flow monitoring, symptom diary, monitor activities of daily living.
♦ Review symptoms and spirometry when possible.
♦ Several visits may be necessary to confirm a diagnosis.
Other tests to consider
To exclude other diagnoses
• Chest x-ray
• Echocardiogram
• Blood tests (complete blood picture)
• Full lung function tests
History
Making a diagnosis
Trial of therapyMJA • Volume 183 Number 1 • 4 July 2005 S39
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asthma and other respiratory conditions.
It is important to consider the required elements of an algo-
rithm, including symptoms and tests (Box). There have been
efforts to determine the positive predictive values of symptoms,
with diagnosis by a doctor as the gold standard. One study
reported that wheezing associated with rest dyspnoea or nocturnal
dyspnoea showed positive predictive values of 42% and 39%,
respectively, for diagnosing asthma.13 Thus, limitations of data in
the literature must be considered in developing the algorithm. The
medical history can provide an indication for the diagnosis at the
level of more likely or less likely to support the diagnosis. Physical
examination is less helpful and usually supports a “rule out” of
more sinister diseases. Tests such as chest x-ray are important to
rule out other diseases, and spirometry has limitations associated
with access, acceptability of definitions of “reversibility”, repeat-
ability of bronchodilator response and quality. Determining the
place of a therapeutic trial or other objective outcomes, such as
functional limitations or activities of daily living, needs further
work and evidence.
Conclusion
An algorithm for general practice would facilitate the use of the
“step-by-step” logic or bundles of information needed in diagnos-
ing asthma. We do not have the perfect approach to asthma
diagnosis, but best current practice needs to be recommended.
Working with GPs will determine the final format of the algorithm.
Evaluation of the effectiveness of any algorithm is a critical
developmental component.
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